Car-t cell therapy for treatment-resistant autoimmune disease
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests an experimental treatment using your own immune cells (called CAR-γδT cells) that target a protein on B cells to calm down autoimmune diseases like lupus, scleroderma, and others. It's for people whose disease hasn't responded to standard treatments, and the goal is to see if it's safe and whether it can reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have been diagnosed with one of these autoimmune conditions: lupus (SLE), scleroderma, inflammatory myositis, ANCA-associated vasculitis, or low platelets tied to connective tissue disease
- Your disease must have failed standard treatment (like steroids with another immunosuppressant) for at least 6 months, or come back after getting better
- A blood test must show your B cells have CD19 or BCMA on them
- Your major organs (like bone marrow, liver, kidney) must work well enough, and you must not have other serious health problems like active infections or recent cancer
- Be willing to use contraception or avoid sex during treatment and for at least 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new Refractory/Relapsed Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.